Last deal

$140M

Amount

Post-IPO Equity

Stage

03.01.2024

Date

3

all rounds

$379.5M

Total amount

date founded

Financing round

General

About Company
Keros is a biopharmaceutical company developing treatments for blood and bone disorders.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2015

Number of employees

Company Type

For Profit

Last funding type

Post-IPO Equity

IPO status

Private

Description

Keros is focused on discovering and commercializing novel therapies for patients with hematologic and musculoskeletal disorders. They specialize in understanding the role of Transforming Growth Factor-Beta (TGF-ß) proteins, which regulate red blood cell and platelet production, as well as muscle and bone growth. Their lead product candidates, KER-050 and KER-047, are being developed for the treatment of low blood cell counts and anemia in patients with myelodysplastic syndromes and myelofibrosis. Additionally, KER-047 is being investigated for the treatment of fibrodysplasia ossificans progressiva. Keros' third product candidate, KER-012, targets disorders associated with bone loss and pulmonary arterial hypertension. Led by experienced CEO Dr. Jasbir Seehra, Keros Therapeutics is headquartered in Lexington, Massachusetts.
Contacts

Phone number

Social url

Similar Companies
1000
Molecular Partners

Molecular Partners

Molecular Partners is a clinical-stage biopharmaceutical company developing a new class of powerful protein therapies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

Zürich, Switzerland

total rounds

4

total raised

$188.82M
Cascadian Therapeutics

Cascadian Therapeutics

Cascadian Therapeutics is a clinical-stage biopharmaceutical company that develops and sells therapeutic products for cancer treatment.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

Seattle, WA, USA

total rounds

4

total raised

$64.9M
Anchiano Therapeutics

Anchiano Therapeutics

Anchiano is a clinical-stage biopharmaceutical company that develops novel cancer therapies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

Jerusalem, Israel

total rounds

3

total raised

$32.43M
InteKrin

InteKrin

InteKrin Therapeutics develops and commercializes therapeutics for neuroendocrine, metabolic and immune disorders.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Biopharma

Location

Los Altos, CA, USA

total rounds

8

total raised

$66.42M

Financials

Funding Rounds
5
3

Number of Funding Rounds

$379.5M

Money Raised

Their latest funding was raised on 03.01.2024. Their latest round Post-IPO Equity

Date 
Funding Round 
Investors 
Money Raised 
Lead 

Cowen Healthcare Investments

Cowen Healthcare Investments is a financial services firm offering asset management and investment banking.

Sector

Investment Banking and Brokerage Services

Subsector

Diversified Financial Services

Location

New York, NY, USA

count Of Investments

55

count Of Exists

4
Venrock

Venrock

Venrock partners with entrepreneurs to build disruptive, successful companies.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Venture Capital, Financial Services

Location

Palo Alto, CA, USA

count Of Investments

619

count Of Exists

216
OrbiMed

OrbiMed

OrbiMed is a healthcare-focused investment firm managing approximately $5 billion in assets.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Financial Services, Venture Capital, Health Care

Location

New York, NY, USA

count Of Investments

561

count Of Exists

82
Foresite Capital

Foresite Capital

Foresite Capital is a healthcare and life sciences investment firm with $2 billion under management.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Biotechnology, Health Care, Financial Services

Location

San Francisco, CA, USA

count Of Investments

123

count Of Exists

11
Co-Investors
Investors
10
5

Number of lead investors

10

Number of investors

Investor 
Lead 
Round 
Partners 
No
Series A, Series B, Series C
Yes
Series A, Series B, Series C
No
Series A, Series B, Series C

Arkin Bio Ventures

Arkin Holdings is a company dedicated to supporting innovative pharmaceutical, biotech, and medical device technologies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Medical Device, Health Care

Location

Herzliya, Israel

count Of Investments

19
Pontifax

Pontifax

Pontifax is a healthcare-dedicated venture capital firm that finances pharmaceutical and life sciences companies.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Biotechnology, Pharmaceuticals, Health Care

Location

Herzliya, Israel

count Of Investments

97

count Of Exists

9

Ran Nussbaum

Ran Nussbaum is a Co-Founder, Managing Partner, and Partner at The Pontifax Group and Pontifax Ltd. Ran Nussbaum served as the Chief Executive Officer of Biomedix. He was a Partner and General Manager of Israel's largest business intelligence company. His real life experience in the life sciences arena coupled with a 10-year experience in the business intelligence field create a unique blend of skills, enabling him to support companies from inception to commercialization. His work revolves around constant and active involvement in companies, providing them with strategic and business development oversight. He serves as the Chairman of OCON Medical Ltd.

current job

Pontifax
Pontifax

organization founded

1
Partners Innovation Fund

Partners Innovation Fund

The Innovation Fund accelerates healthcare technology development and attracts external capital.

Sector

Closed End Investments

Subsector

Closed End Investments

Location

Boston, MA, USA

count Of Investments

33

count Of Exists

6

People

Founders
1
Jasbir Seehra
Jasbir Seehra

Jasbir Seehra

Jasbir Seehra is the founding CEO of Keros Therapeutics. Jas worked with the academic founders and Pontifax in putting together the strategy and in-licensing of the founding technology. Jas brings more than 30 years of scientific, strategic and operational experience in Biotech industry. Prior to Keros, Seehra was the CSO at Ember Therapeutics, founded by Third Rock Ventures. In 2003, Jas co-founded Acceleron Pharma, focused on biologics inhibiting the TGFb superfamily and served as CSO to the end of 2010. Jas hired the research team that discovered multiple products and manufacturing teams and oversaw the discovery and development of multiple products targeting muscle strength, bone loss and anemia. As founder and member of the executive team, Jas helped raise more than $200M capital from venture fund and corporate partnerships with Celgene and Shire.

current job

Keros Therapeutics
Keros Therapeutics

organization founded

1

Jasbir Seehra

Employee Profiles
5
Christopher Rovaldi

Christopher Rovaldi

COO

Annita Tanini

Annita Tanini

Vice President of Finance, Controller

Rachel Barger

Head of clinical development operations

Jennifer Lachey

Vp, biology and pharmacology

Jasbir Seehra

Jasbir Seehra

CEO

Activity

Recent News
9
News Timeline

The graph reveals the ratio (%) of positive news articles in a chosen time range

month